CD73 inhibitors present significant opportunities in cancer immunotherapy by reversing immunosuppression in tumors and enhancing immune response. Novel antibodies, RNA, and small molecules are in ...
Detailed price information for Pds Biotechnology Corp (PDSB-Q) from The Globe and Mail including charting and trades.
HCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cellsBPD is ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
CCR8-targeted immunotherapies offer significant opportunities in cancer treatment by selectively depleting immunosuppressive Tregs, enhancing anti-tumor immunity. This emerging target is ideal for ...
CREATE Medicines is working on a clinical-stage pipeline for cancer, while its autoimmune programs are still in preclinical ...
Issued on behalf of GT Biopharma, Inc.After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, ...
An update from AC Immune SA ( (ACIU)) is now available. AC Immune has convened its 2026 Annual General Meeting for June 11, 2026, publishing the invitation and proxy materials and asking shareholders ...
Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy ...
Mayo Clinic researchers have identified an immune-regulating molecule that may help explain why some patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, ...
As the wave of in vivo CAR-T hype crests, Create Medicines is catching the swell with a $122 million series B meant to back ...
NKT therapy, agenT-797, delivers context-dependent immune reprogramming showing activation in cancer and anti-inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results